Human acute lymphoblastic leukemia (ALL) cell line BV173, that exhibits Imatinib mesylate (IM) resistance due to the expression of BCR/ABL kinase harboring the E255K mutation.
Imatinib mesylate (IM) represents a primary treatment option for individuals with chronic myelogenous leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). However, patients often acquire IM resistance via mutations in the Bcr/Abl kinase domain, which reportedly account for 50-90% of acquired resistance. The E255K along with T315I mutations are the most two frequently observed in IM-resistant patients.
From the laboratories of Steven Grant, MD, Virginia Commonwealth University.
Part of The Investigator's Annexe program.
|Product Type:||Cell Line|
|Cell Type:||B cell precursor leukemia (ALL)|
|Morphology:||Round to elongated, single cells in suspension|
|Source:||BV173 cell line|
|Organism:||Human peripheral blood|
|Subculturing:||Seed out at density 0.3-1 x 106 cells/ml; split saturated culture 1:2 to 1:3 every 2-3 days|
|Growth Conditions:||80-90 % RPMI 1640 + 10-20% FBS|
|Cryopreservation:||90% FBS + 10% DMSO|
If you publish research with this product, please let us know so we can cite your paper.